Global Manufacturing of CAR T Cell Therapy
By B. Levine, J. Miskin, K. Wonnacott, C. Keir. Molecular Therapy: Methods & Clinical Development, 2016
675 citations recorded by the source corpus.
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types. Chimeric antigen receptor T cells are generated by removing T cells from a patient's blood and engineering the cells to express the chimeric antigen receptor, which reprograms the T cells to target tumor cells. As chimeric antigen receptor T cell therapy moves into later-phase clinical trials and becomes an option for more patients, compliance of the chimeric antigen receptor T cell manufacturing process with global regulatory requirements becomes a topic for extensive discussion. Additionally, the challenges of taking a chimeric antigen receptor T cell manufacturing process from a single institution to a large-scale multi-site manufacturing center must be addressed. We have anticipated such concerns in our experience with the CD19 chimeric antigen receptor T cell therapy CTL019. In this review, we discuss steps involved in the cell processing of the technology, including the use of an optimal vector for consistent cell processing, along with addressing the challenges of expanding chimeric antigen receptor T cell therapy to a global patient population.
Subfields: Biomedical Engineering, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/b8c4f542ebcd7fada92f4a7ff708529e5de82196
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Clinical use of lentiviral vectors (2018, background): “Following purification, the eluted fractions undergo a series of filtration steps for sterilization purposes and to remove any remaining cellular debris [62, 63].”